Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings
TARS·Reported November 13, 2024·After market close
Tarsus Pharmaceuticals, Inc. reported Q3 2024 revenue of $48.1M, beat analyst consensus of $43.2M by $4.9M. Diluted EPS came in at $-0.61, beat the $-0.94 consensus by $0.33.
Revenue
$48.1Mbeat by $4.9M
Consensus: $43.2MDiluted EPS
$-0.61beat by $0.33
Consensus: $-0.94
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Tarsus Pharmaceuticals, Inc.'s Q3 2024 earnings report.
Tarsus Pharmaceuticals, Inc. (TARS) reported Q3 2024 earnings on November 13, 2024 after market close.
Tarsus Pharmaceuticals, Inc. reported revenue of $48.1M and diluted EPS of $-0.61 for Q3 2024.
Revenue beat the consensus estimate of $43.2M by $4.9M. EPS beat the consensus estimate of $-0.94 by $0.33.
You can read the 10-Q periodic report (0001819790-24-000129) directly on SEC EDGAR. The filing index links above go to sec.gov.